BICYCLE THERAPEUTICS PLC

BCYC

$759M

Small Cap

NASDAQPharmaceutical Preparations🇺🇸North AmericaCAMBRIDGE305 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 15, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

3 upcoming, 0 past

Phase 2Next

BT8009 Phase 2 Results Expected

March 2026~BT8009329

Primary completion for BT8009 trial (NCT04561362) in Urinary Bladder Neoplasm

Source

Phase 2

BT5528 Phase 2 Results Expected

Jul 31, 2026BT5528288

Primary completion for BT5528 trial (NCT04180371) in Advanced Solid Tumor Historically Known for High EphA2 Expression

Source

Phase 2

Nivolumab Phase 2 Results Expected

August 2026~BT7480200

Primary completion for Nivolumab trial (NCT04180371) in Advanced Solid Tumor Historically Known for High EphA2 Expression

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

BT8009

Phase 3

Urinary Bladder Neoplasm

Gemcitabine + cisplatin Or carboplatin

Phase 3

Metastatic Urothelial Cancer

Zelenectide pevedotin (BT8009)

Phase 2

Non-Small Cell Lung Cancer

BT5528

Phase 2

Advanced Solid Tumor Historically Known for High EphA2 Expression

BT7480

Phase 2

Advanced Solid Tumor

Drug Name	Phase	Indication	Designations
BT8009	Phase 3	Urinary Bladder Neoplasm	-
Gemcitabine + cisplatin Or carboplatin	Phase 3	Metastatic Urothelial Cancer	-
Zelenectide pevedotin (BT8009)	Phase 2	Non-Small Cell Lung Cancer	-
BT5528	Phase 2	Advanced Solid Tumor Historically Known for High EphA2 Expression	-
BT7480	Phase 2	Advanced Solid Tumor	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

BCYC News